Published • loading... • Updated
New data on RevMed’s Rasonque leave potential opening for other treatments
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
New data on RevMed’s Rasonque leave potential opening for other treatments
Patients with the most common KRAS mutation in pancreatic cancer appeared to have a lower response rate than the overall patient population with Revolution Medicines’ Rasonque, sending the company’s shares {$RVMD} down more than 6% ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
